No business profile yet.
Size CHO Pharma (6586.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $488M, the 438th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$80.40 on 18 Nov 2026.
Performance Over six months the shares gained 23.9%, against -14.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 18 in its peer set.
Growth Revenue fell 46.9% over the last twelve months (peer median -4.0%); the operating margin is -17,694.3% (peer median -11.6%).
Valuation It trades at 8,281.1× enterprise value to sales against a peer median of 7.5× (most expensive of 14).
Capital Return on invested capital runs 66.9 points below its cost of capital (9.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.71M | NT$1.43M | NT$3.58M | NT$0 | NT$60,000 |
| Revenue growth | — | -60% | — | -100% | — |
| Gross profit | -NT$22.6M | -NT$25.5M | -NT$23.8M | -NT$28.3M | -NT$35.8M |
| EBITDA | -NT$278M | -NT$299M | -NT$223M | -NT$241M | -NT$315M |
| Net income | -NT$268M | -NT$290M | -NT$212M | -NT$306M | -NT$338M |
| Free cash flow | -NT$250M | -NT$289M | -NT$223M | -NT$293M | -NT$259M |
| Capital expenditure | NT$10.9M | NT$11.7M | NT$5.49M | NT$2.00M | NT$9.40M |
| Total debt | n/a | NT$14.6M | NT$28.9M | NT$0 | NT$11.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6586.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.2% | -10.2% | 5th lowest of 21 |
| 6-month return | +23.9% | -14.1% | 3rd highest of 18 |
| Distance from 52-week high | -45.9% | -44.8% | 11th highest of 21 |
| Revenue growth (TTM) | -46.9% | -4.0% | 3rd lowest of 15 |
| Operating margin | -17,694.3% | -11.6% | lowest of 15 |
| EV / Sales | 8,281.1× | 7.5× | most expensive of 14 |
| ROIC minus cost of capital | -66.9 pp | -5.7 pp | 2nd lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |